Here’s whether Insmed, Inc. (INSM) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Caution.
🟡
Caution
Positives: above the 50-day MA (medium-term momentum positive); RSI 41 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); 50-day MA is falling (-3.04% over 10 days); 3-month momentum negative (-20.9%). Currently 49.7% off its 52-week high. Score: -2/7.
INSM is trading below its 200-day MA ($149.12) — a key warning sign the longer-term trend is under pressure. An RSI of 41.3 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +3.3% compares to +16.5% for SPY (trailed the market by 13.2%). The current 49.7% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.
$10,000 invested 1 year ago→ $10,328 today
vs. S&P 500 (SPY) — same period trailed market by 13.2%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✗Above 200-day MA ($149.12)
✓Above 50-day MA ($105.79)
✓RSI(14) neutral zone (30–70) — currently 41.3
✓Positive return (+3.3%)
!Within 10% of period high (−49.7%)
Period Range $106.92
$90.39$212.75
RSI (14) 41.3
0 · OversoldOverbought · 100
Key Metrics
Price$106.92
Period Return+3.3%
Period High$212.75
Period Low$90.39
Drawdown−49.7%
MA-50$105.79
MA-200$149.12
RSI (14)41.3
Avg Volume (30d)3.7M
vs. SPYtrailed by 13.2%
Return Rank#491 of 999
Trend Signals
Price is below the 200-day moving average ($149.12)
Price is above the 50-day moving average ($105.79)